US 11,987,827 B2
Tethering cysteine residues using cyclic disulfides
Jeffrey N. Agar, Newton, MA (US); and Joseph Salisbury, Cranston, RI (US)
Assigned to Brandeis University, Waltham, MA (US)
Filed by Brandeis University, Waltham, MA (US)
Filed on Jan. 13, 2022, as Appl. No. 17/574,742.
Application 17/574,742 is a division of application No. 16/882,035, filed on May 22, 2020, granted, now 11,254,923.
Application 16/882,035 is a division of application No. 15/912,197, filed on Mar. 5, 2018, granted, now 10,689,639, issued on Jun. 23, 2020.
Application 15/912,197 is a division of application No. 15/219,807, filed on Jul. 26, 2016, granted, now 9,944,919, issued on Apr. 17, 2018.
Application 15/219,807 is a division of application No. 14/440,978, granted, now 9,428,589, issued on Aug. 30, 2016, previously published as PCT/US2013/070239, filed on Nov. 15, 2013.
Claims priority of provisional application 61/726,776, filed on Nov. 15, 2012.
Prior Publication US 2022/0135961 A1, May 5, 2022
Int. Cl. C12N 9/96 (2006.01); A61K 31/095 (2006.01); A61K 31/385 (2006.01); C07K 19/00 (2006.01); C12N 9/02 (2006.01)
CPC C12N 9/96 (2013.01) [A61K 31/095 (2013.01); A61K 31/385 (2013.01); C07K 19/00 (2013.01); C12N 9/0089 (2013.01); C12Y 115/01001 (2013.01); C07K 2319/00 (2013.01)] 13 Claims
 
1. A method of treating a patient suffering from Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, or Alzheimer's disease, wherein said method comprises administering to the patient a stabilized superoxide dismutase (SOD1) dimer, wherein said stabilized superoxide dismutase dimer has a tertiary structure and comprises a first SOD1 monomer and a second SOD1 monomer; wherein the first SOD1 monomer comprises a first cysteine residue; the second SOD1 monomer comprises a second cysteine residue, and wherein said first SOD1 monomer and said second SOD1 monomer has at least 85% sequence identity to SEQ ID NO:2; and wherein the first cysteine residue is connected to the second cysteine residue by a dithiolane-4,4-dimethanol.